Skip to main content
. Author manuscript; available in PMC: 2021 Nov 15.
Published in final edited form as: Clin Cancer Res. 2021 Feb 22;27(10):2938–2946. doi: 10.1158/1078-0432.CCR-20-4221

Figure 1. CD276 expression in pediatric patient-derived and cell line-derived xenograft models.

Figure 1.

A) RNAseq expression data for CD276 in pediatric solid tumors (TARGET, Treehouse) and normal tissue samples (GTEx database). B) CD276 mRNA expression from PPTC RNAseq data in nine solid pediatric tumor histologies present in this study (ATRT 6; Ewing sarcoma 9; extracranial Rhabdoid 4; embryonal rhabdomyosarcoma (RMS) 6; alveolar RMS 6; hepatoblastoma 1; neuroblastoma 33; osteosarcoma 30; Wilms tumor 12). Black points in panel B indicate models examined in N>1 or SMT study (of 62 unique models tested, 37 had RNA-sequencing data).